UK Stocks-Factors to watch on October 2 (updated)
UPDATE 1-UK Stocks-Factors to watch on October 2 Adds new items
Oct 2 (Reuters) - Britain's FTSE 100 .FTSE index is seen opening up on Friday, with futures FFIc1 up 0.3%.
* CAPITA: Britain's Capita CPI.L has been hit with a fresh government review over its handling of the troubled civil service pension scheme, with the outsourcing firm saying on Friday that its performance remains below expected standards.
* J D WETHERSPOON: British pub chain J D Wetherspoon JDW.L on Friday posted an 8.6% rise in like-for-like sales at the start of its fiscal 2027, as hot weather drew more customers to its facilities.
* UK'S CMA: Britain's competition watchdog said on Friday it had provisionally found that Nexfibre's acquisition of fibre broadband operator Netomnia could substantially reduce competition in the wholesale supply of fixed broadband services.
* ASTRAZENECA: AstraZeneca AZN.L and Daiichi Sankyo 4568.T said on Friday that they have entered into a clinical collaboration with Summit Therapeutics SMMT.O to test their cancer drug Datroway in combination with Summit's ivonescimab across multiple tumour types, including lung and breast cancers.
* BAE SYSTEMS: BAE Systems BAES.L is among the potential bidders that are in the early stages of exploring an offer for Robin Radar Systems.
* HOME REIT: More than 800 investors have sued Home REIT HOMEH.L alleging they were misled about the security of its rental income, financial strength, and social impact.
* DEMENTIA: UK's national research agency is backing a plan to speed up dementia testing with up to £80 million in funding, to improve diagnosis rates and cut waiting times that can exceed a year.
* COMMODITIES: Oil prices were broadly stable on Friday, Gold steadied but was still headed for a second consecutive weekly decline, and Copper recovered some of the previous days' losses on supply concerns
* For more on the factors affecting European stocks, please click on: LIVE/
TODAY'S UK PAPERS
> Financial Times PRESS/FT
> Other business headlines PRESS/GB
(Compiled by Anushka Chourasia and Krisha Bhatt in Bengaluru)
Recent news on AstraZeneca
See all newsUltomiris approved in US in IgAN
AstraZeneca says FDA approves drug for rare kidney disease in adults
AstraZeneca-Amgen asthma drug hits 69% remission in esophageal disease trial
Early US flu season, current strain may signal risk for younger people; doctors urge shots
AstraZeneca partners with Oracle for AI-driven clinical trials